Health Care Innovation

Business & Economics

Product Liability Law, FDA Pre-Emption, and Public Opinion

On December 3, the U.S. Supreme Court began to hear Wyeth v. Levine, which will determine whether the FDA’s regulations governing the labels of prescription drugs “pre-empt” state tort laws. I’ve already discussed the details of the case, wherein Wyeth (the manufacturer) claims that the Vermont state court had no ...
Commentary

Health Plans Belly Up to SCHIP Trough

For those of us who believe that American families should control our health-care dollars, instead of government, employers, or other 3rd parties, the recent behavior of health-care lobbyists in DC is disturbing. A key insight of the political philosophy of “public choice” theory is that it is impossible for politicians ...
Business & Economics

Gov. Schwarzenegger’s veto traps California in obsolete medical research

Eureka Reporter, November 4, 2008 Sacramento Union, November 12, 2008 SACRAMENTO – Last month Governor Arnold Schwarzenegger proclaimed September 25 “Stem Cell Awareness Day.” That news got by many Californians, who remain unaware of how California is locked into paying for obsolete research, certain to consume billions of dollars but ...
California

State off course on ‘personal genomics’

California officials recently ordered two “personal genomics” firms to cease and desist operations within the state. The companies eventually were allowed to continue operations – with a few more regulatory conditions – but why did the state demand that they shut down in the first place? The Silicon Valley startups, ...
Commentary

Five Myths About Health Care

Forbes.com, November 1, 2008 RealClearPolitics.com, November 1, 2008 Sen. Barack Obama has drawn many voters to his side, thanks in no small part to his health care plan. Unfortunately, his proposals rest upon several falsehoods that are all too common in the health care debate. Using his own words, let’s ...
Commentary

Gov’t Control of Health Care Unravelling? CVS Gives Cash Discounts for Generic Drugs

While state and federal governments flail around trying to unbreak the health care “system” that they’ve been breaking for decades, entrepreneurs are addressing patients’ needs in innovative ways. CVS, a leading chain of pharmacies has now cut prices for 400 generic drugs to $9.99 for a 90-day supply. A key ...
Commentary

Newsflash! Women Have Different Health Costs Than Men!

Surely, Robert Pear’s article in today’s New York Times, “Women buying health policies pay a penalty”, falls under the category of “old news”. (So old, indeed, that my former colleague Diana Ernst addressed it last year.) Calling it a “penalty”, rather than an actuarially fair premium, is also an old ...
Business & Economics

It’s a Lock: Governor’s veto traps California in obsolete medical research

SACRAMENTO – Last month Governor Arnold Schwarzenegger proclaimed September 25 “Stem Cell Awareness Day.” That news got by many Californians, who remain unaware of how California is locked into paying for obsolete research, certain to consume billions of dollars but unlikely to come up with any of the cures Californians ...
Business & Economics

Product-Liability Law: Is “Pre-emption” the Right Question?

The media are (justifiably) interested in the Bush administration’s (or, if you prefer, the “Bush regime’s”) rushing a bunch of new rules into the Code of Federal Regulations that would “pre-empt” states’ product-liability laws. According to the Wall Street Journal, these rules “could block product-safety lawsuits by consumers and states.” ...
Commentary

SCHIP: Big Pharma Falls Into Line with Big Government

The Wall Street Journal confirms the depressing news that the brand-name pharmaceutical industry has been “collaborating” with advocates of a government take-over of health care. Apparently, it has given $13.2 million to an “astroturf” outfit, “America’s Agenda: Health Care for Kids”, to produce and run advertisements stroking 28 Congressmen (of ...
Business & Economics

Product Liability Law, FDA Pre-Emption, and Public Opinion

On December 3, the U.S. Supreme Court began to hear Wyeth v. Levine, which will determine whether the FDA’s regulations governing the labels of prescription drugs “pre-empt” state tort laws. I’ve already discussed the details of the case, wherein Wyeth (the manufacturer) claims that the Vermont state court had no ...
Commentary

Health Plans Belly Up to SCHIP Trough

For those of us who believe that American families should control our health-care dollars, instead of government, employers, or other 3rd parties, the recent behavior of health-care lobbyists in DC is disturbing. A key insight of the political philosophy of “public choice” theory is that it is impossible for politicians ...
Business & Economics

Gov. Schwarzenegger’s veto traps California in obsolete medical research

Eureka Reporter, November 4, 2008 Sacramento Union, November 12, 2008 SACRAMENTO – Last month Governor Arnold Schwarzenegger proclaimed September 25 “Stem Cell Awareness Day.” That news got by many Californians, who remain unaware of how California is locked into paying for obsolete research, certain to consume billions of dollars but ...
California

State off course on ‘personal genomics’

California officials recently ordered two “personal genomics” firms to cease and desist operations within the state. The companies eventually were allowed to continue operations – with a few more regulatory conditions – but why did the state demand that they shut down in the first place? The Silicon Valley startups, ...
Commentary

Five Myths About Health Care

Forbes.com, November 1, 2008 RealClearPolitics.com, November 1, 2008 Sen. Barack Obama has drawn many voters to his side, thanks in no small part to his health care plan. Unfortunately, his proposals rest upon several falsehoods that are all too common in the health care debate. Using his own words, let’s ...
Commentary

Gov’t Control of Health Care Unravelling? CVS Gives Cash Discounts for Generic Drugs

While state and federal governments flail around trying to unbreak the health care “system” that they’ve been breaking for decades, entrepreneurs are addressing patients’ needs in innovative ways. CVS, a leading chain of pharmacies has now cut prices for 400 generic drugs to $9.99 for a 90-day supply. A key ...
Commentary

Newsflash! Women Have Different Health Costs Than Men!

Surely, Robert Pear’s article in today’s New York Times, “Women buying health policies pay a penalty”, falls under the category of “old news”. (So old, indeed, that my former colleague Diana Ernst addressed it last year.) Calling it a “penalty”, rather than an actuarially fair premium, is also an old ...
Business & Economics

It’s a Lock: Governor’s veto traps California in obsolete medical research

SACRAMENTO – Last month Governor Arnold Schwarzenegger proclaimed September 25 “Stem Cell Awareness Day.” That news got by many Californians, who remain unaware of how California is locked into paying for obsolete research, certain to consume billions of dollars but unlikely to come up with any of the cures Californians ...
Business & Economics

Product-Liability Law: Is “Pre-emption” the Right Question?

The media are (justifiably) interested in the Bush administration’s (or, if you prefer, the “Bush regime’s”) rushing a bunch of new rules into the Code of Federal Regulations that would “pre-empt” states’ product-liability laws. According to the Wall Street Journal, these rules “could block product-safety lawsuits by consumers and states.” ...
Commentary

SCHIP: Big Pharma Falls Into Line with Big Government

The Wall Street Journal confirms the depressing news that the brand-name pharmaceutical industry has been “collaborating” with advocates of a government take-over of health care. Apparently, it has given $13.2 million to an “astroturf” outfit, “America’s Agenda: Health Care for Kids”, to produce and run advertisements stroking 28 Congressmen (of ...
Scroll to Top